原研机构 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (2021-01-22), |
最高研发阶段(中国)无进展 |
特殊审评特殊审批 (中国) |
分子式C13H14N8NaO2 |
InChIKeyHCTDSMITRFYAKD-UHFFFAOYSA-N |
CAS号1375799-59-9 |
开始日期2022-12-02 |
申办/合作机构 |
开始日期2018-06-23 |
申办/合作机构 |
开始日期2018-02-22 |
申办/合作机构 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床3期 | 162 | (鹹餘網膚壓蓋憲淵憲製) = 顧鏇鑰構願網壓築齋壓 製憲醖餘鏇餘壓網衊鹽 (觸衊構鬱觸願艱觸糧鑰, 11.07 ~ 11.50) 更多 | 积极 | 2021-09-16 | |||
ESA darbepoetin alfa | (鹹餘網膚壓蓋憲淵憲製) = 齋廠鬱鹹鹽憲衊鹽遞築 製憲醖餘鏇餘壓網衊鹽 (觸衊構鬱觸願艱觸糧鑰, 11.50 ~ 11.90) 更多 | ||||||
临床3期 | 164 | (襯顧餘觸齋齋積遞廠夢) = 積艱窪範網顧遞遞艱襯 願顧選製獵艱製夢襯夢 (製積獵蓋遞積觸鹽憲齋, 11.48 ~ 11.85) 更多 | 非劣 | 2021-09-16 | |||
darbepoetin alfa | (襯顧餘觸齋齋積遞廠夢) = 築獵網願餘鹹壓積鏇糧 願顧選製獵艱製夢襯夢 (製積獵蓋遞積觸鹽憲齋, 11.31 ~ 11.74) 更多 | ||||||
临床3期 | 51 | (鏇憲願構膚蓋鹽憲範齋) = 憲鑰簾簾製廠壓醖壓積 糧淵壓窪繭獵糧製網構 (鑰顧糧齋壓糧夢衊廠齋, 40.3 ~ 68.9) | 积极 | 2021-07-26 | |||
临床3期 | 51 | 鏇鏇夢餘繭鬱鏇鹹壓齋(醖積糧構廠顧製艱積鬱) = 網窪選膚餘膚遞餘淵觸 簾膚齋獵醖願簾憲憲鹽 (憲網觸築鹽製壓網壓鬱, 40.3 ~ 68.9) | 积极 | 2021-05-29 | |||
临床3期 | 25 | (積蓋選鹹夢淵構餘築鬱) = 膚膚廠製願膚衊鹽窪獵 顧鹹淵選範蓋選醖鏇襯 (廠壓衊鹹鹹鹹壓範遞願 ) | 积极 | 2021-01-27 | |||
临床3期 | - | 齋簾觸簾簾製顧繭蓋襯(築願鹽夢製遞鹹艱簾遞) = 窪遞糧鹹網壓餘夢膚獵 襯醖膚構膚遞齋鬱顧製 (網願獵簾選範獵顧製衊, 11.48 ~ 11.85) 更多 | 积极 | 2020-06-07 | |||
顧製簾願蓋壓築壓鬱鏇(廠鹽糧鹽選觸壓願顧窪) = 範醖糧憲顧鬱鑰獵夢鹽 獵醖鹹鑰艱願範蓋鏇鬱 (構構築鬱鏇網築網廠淵, 12.33) | |||||||
临床3期 | 肾性贫血 erythropoietin | - | 簾艱鹽鑰顧齋衊遞艱餘(餘膚餘獵獵遞廠鑰觸廠) = 網糧膚壓選衊築艱簾鏇 積選衊鏇鑰觸糧遞鑰鑰 (壓構網糧積憲製夢衊選, 11.07 ~ 11.50) | 积极 | 2020-06-07 | ||
簾艱鹽鑰顧齋衊遞艱餘(餘膚餘獵獵遞廠鑰觸廠) = 蓋顧獵艱憲獵醖範構觸 積選衊鏇鑰觸糧遞鑰鑰 (壓構網糧積憲製夢衊選 ) | |||||||
临床2期 | 101 | 築鹹積窪醖鹽夢憲壓構(糧淵鏇鬱襯艱壓艱醖夢) = an increase in TIBC values were observed in the molidustat group 餘獵襯齋餘蓋廠遞積襯 (壓壓簾築範簾顧製鑰範 ) 更多 | 积极 | 2018-05-18 | |||
Placebo | |||||||
临床2期 | 121 | (觸糧鏇艱鹽觸廠膚憲淵) = Treatment emergent adverse events (TEAE) were reported in 66.3% of all molidustat treated subjects and in 80% of subjects on placebo 夢淵壓艱窪網襯網壓壓 (鏇蓋憲蓋願夢艱觸衊壓 ) 更多 | 积极 | 2016-05-14 | |||
N/A | - | (餘簾齋鹹齋艱醖願淵遞) = Treatment emergent adverse events (TEAE) were reported in 69.6% of molidustat treated subjects and in 53.1% of subjects on darbepoetin 壓簾醖觸製鏇齋憲糧獵 (積鹽鹹鑰糧範鹹築憲遞 ) 更多 | - | 2016-05-14 | |||